Patents by Inventor Xiaoxi YUAN

Xiaoxi YUAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF
    Publication number: 20250002502
    Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.
    Type: Application
    Filed: December 20, 2022
    Publication date: January 2, 2025
    Inventors: Jinming LIU, Yun REN, Xiaoyong LI, Xiaoxi YUAN, YUngang ZHANG, Qiang TIAN, Hongmei SONG, Junyou GE
  • Use of anti-HER2 antibody-drug conjugate in cancer treatment
    Patent number: 12150944
    Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 26, 2024
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Hongmei Song, Xiaoxi Yuan, Jing Wang, Liang Xiao, Tongtong Xue, Ping Liu, Lichun Wang, Jingyi Wang
  • ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240269312
    Abstract: Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).
    Type: Application
    Filed: May 23, 2022
    Publication date: August 15, 2024
    Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
    Inventors: Haijun TIAN, Qiang TIAN, Xiaoxi YUAN, Ying-Hua CHANG, Deliang LI, Jiangjiang HU, Yitao ZHANG, Xiaobei WANG, Yong ZHENG, Jian YE, Bo WANG, Yu MIAO, Bingqiang KANG, Fen LI, Zujian TANG, Hanwen DENG, Hongmei SONG, Junyou GE, Jingyi WANG
  • Recombinant bispecific antibodies to PD-L1 and CTLA-4
    Patent number: 11421029
    Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: August 23, 2022
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Liang Xiao, Dengnian Liu, Hu Long, Jiangjiang Hu, Yamin Cui, Xiaoxi Yuan, Lichun Wang, Jingyi Wang
  • Use of Anti-HER2 Antibody-Drug Conjugate in Cancer Treatment
    Publication number: 20210000970
    Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.
    Type: Application
    Filed: April 30, 2019
    Publication date: January 7, 2021
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Hongmei SONG, Xiaoxi YUAN, Jing WANG, Liang XIAO, Tongtong XUE, Ping LIU, Lichun WANG, Jingyi WANG
  • RECOMBINANT BISPECIFIC ANTIBODY
    Publication number: 20200216538
    Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 9, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Liang XIAO, Dengnian LIU, Hu LONG, Jiangjiang HU, Yamin CUI, Xiaoxi YUAN, Lichun WANG, Jingyi WANG